Adverse effects of modified release oxycodone/naloxone in patients with moderate to severe liver impairment

• 1 Royal North Shore Hospital, Sydney, NSW
• 2 University of Sydney, Sydney, NSW
• 3 AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW

---

• 1. TGA eBusiness Services. Product Information TARGIN modified release tablets. Sydney: Mundipharma; 2017. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2012-PI-01399-3&d=2018033116114622483 (viewed Mar 2018).
• 2. Franklin AE, Lovell MR, Boyle F. A case of opioid toxicity on conversion from extended-release oxycodone and naloxone to extended-release oxycodone in a patient with liver dysfunction. J Pain Symptom Manage 2017; 53: e1-e2.
• 3. Lau F, Gardiner M. Oxycodone/naloxone: an unusual adverse drug reaction. Aust Fam Physician 2017; 46: 42-43.
• 4. Smith K, Hopp M, Mundin G, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 2012; 50: 360-367.
• 5. Tovoli F, De Lorenzo S, Samolsky Dekel BG, et al. Oral oxycodone/naloxone for pain control in cirrhosis: observational study in patients with symptomatic metastatic hepatocellular carcinoma. Liver Int 2018; 38: 278-284.